- Home
- BTM vs TNXP Comparison
BTM vs TNXP Comparison
Compare BTM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- TNXP
- Stock Information
- Founded
- BTM 2016
- TNXP 2007
- Country
- BTM United States
- TNXP United States
- Employees
- BTM N/A
- TNXP N/A
- Industry
- BTM Finance: Consumer Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- TNXP Health Care
- Exchange
- BTM Nasdaq
- TNXP Nasdaq
- Market Cap
- BTM 266.2M
- TNXP 213.7M
- IPO Year
- BTM N/A
- TNXP N/A
- Fundamental
- Price
- BTM $2.66
- TNXP $17.77
- Analyst Decision
- BTM Strong Buy
- TNXP Buy
- Analyst Count
- BTM 2
- TNXP 1
- Target Price
- BTM $6.25
- TNXP $70.00
- AVG Volume (30 Days)
- BTM 1.6M
- TNXP 760.3K
- Earning Date
- BTM 11-13-2025
- TNXP 11-07-2025
- Dividend Yield
- BTM N/A
- TNXP N/A
- EPS Growth
- BTM N/A
- TNXP N/A
- EPS
- BTM 0.12
- TNXP N/A
- Revenue
- BTM $608,432,000.00
- TNXP $9,831,000.00
- Revenue This Year
- BTM $10.81
- TNXP $14.79
- Revenue Next Year
- BTM $6.91
- TNXP $933.49
- P/E Ratio
- BTM $20.29
- TNXP N/A
- Revenue Growth
- BTM N/A
- TNXP N/A
- 52 Week Low
- BTM $0.93
- TNXP $6.76
- 52 Week High
- BTM $6.88
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- BTM 39.36
- TNXP 33.43
- Support Level
- BTM $2.45
- TNXP $18.53
- Resistance Level
- BTM $2.79
- TNXP $18.96
- Average True Range (ATR)
- BTM 0.15
- TNXP 1.01
- MACD
- BTM 0.01
- TNXP 0.38
- Stochastic Oscillator
- BTM 37.22
- TNXP 17.09
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.